<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="other" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
  <front>
    <journal-meta>
      <journal-id journal-id-type="pmc">JRMS</journal-id>
      <journal-id journal-id-type="pubmed">J Res Med Sci</journal-id>
      <journal-id journal-id-type="publisher-id">Journal of Research in Medical Sciences</journal-id>
      <journal-title>Journal of Research in Medical Sciences</journal-title>
      <issn pub-type="ppub">1735-1995</issn>
	<issn pub-type="epub">1735-7136</issn>
      <publisher>
        <publisher-name>Medknow Publications Pvt Ltd</publisher-name>
	<publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">JRMS-17-962</article-id>
      <article-id pub-id-type="pmid">23825998</article-id>
      <article-categories>
	<subj-group subj-group-type="headings">
		<subject>Original Article</subject>
	</subj-group>
      </article-categories>
      <title-group>
        <article-title>The stromelysin-1 5A/5A genotype enhances colorectal cancer cell invasion in Iranian population</article-title>
      </title-group>
	<contrib-group>
<contrib contrib-type="author">
<name><surname>Motovali-Bashi</surname>
<given-names>Majid</given-names></name>
<xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib>
<contrib contrib-type="author">
<name><surname>Hojati</surname>
<given-names>Zohreh</given-names></name>
<xref ref-type="aff" rid="aff2"/></contrib>
<contrib contrib-type="author">
<name><surname>Hajihoseiny</surname>
<given-names>Samaneh</given-names></name>
<xref ref-type="aff" rid="aff3"/></contrib>
<contrib contrib-type="author">
<name><surname>Hemmati</surname>
<given-names>Simin</given-names></name>
<xref ref-type="aff" rid="aff4"/></contrib>
</contrib-group>
<aff id="aff1">Department of Biology, Genetic Division, Faculty of Sciences, University of Isfahan, Isfahan, Iran</aff><aff id="aff2">Department of Biology, Genetic Division, Faculty of Sciences, University of Isfahan, Isfahan, Iran</aff><aff id="aff3">Department of Biology, Genetic Division, Faculty of Sciences, University of Isfahan, Isfahan, Iran</aff><aff id="aff4">Department of Oncology and Radiotherapy, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</aff>

      <author-notes>
	<corresp id="cor1"><bold>Address for correspondence:</bold>Majid Motovali-Bashi, Department of Biology, Genetic Division, Faculty of Sciences, University of Isfahan,Hezar Jerib St., Isfahan, Iran <email xlink:href="mbashi@sci.ui.ac.ir">mbashi@sci.ui.ac.ir</email></corresp>

      </author-notes>
      <pub-date pub-type="ppub">
        <season>October</season>
        <year>2012</year>
      </pub-date>
      <volume>17</volume>
      <issue>10</issue>
      <fpage>962</fpage>
      <lpage>966</lpage>   
      
<history>
<date date-type="received"><day>7</day><month>7</month><year>2011</year></date>

<date date-type="rev-recd"><day>16</day><month>8</month><year>2012</year></date>
</history>

      <permissions>
        <copyright-statement>Copyright: &#x000a9; Journal of Research in Medical Sciences</copyright-statement>
        <copyright-year>2012</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
</license>
      </permissions>
      <abstract><sec id="st1"><title>Background:</title><p> Matrix metalloproteinases comprise a family of enzyme degrade components of extra cellular matrix. There are single nucleotide polymorphisms in the promoter regions of several genes with ability to influence cancer susceptibility. The aim of this study was to analyze association between MMP3 promoter polymorphisms and colorectal cancer occurrence and progression. <sec id="st1"><title>Materials and Methods:</title><p> In this case-control study 120 colorectal cancer patients and 100 controls were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) on the genomic deoxyribonucleic acid (DNA). The patients group was divided into different subgroups: a subgroup without metastatic activity (M <sup>-</sup> ) and a subgroup that had developed metastasis (M <sup>&#x002B;</sup> ). <sec id="st1"><title>Results:</title><p> There was a significant difference in frequency of the MMP-3 genotype between cases and controls (&#967;&#898; = 16.17; P = 0.0003). The 5A homozygote in patients and controls was significantly different. The frequency of the 5A allele among affected patients (67.91&#x0025;) was significantly higher than among the healthy controls (49&#x0025;; &#967;&#178; = 16.17, P = 0.00005). At the time of diagnosis, individual who was carrying the 5A allele was more represented in the M <sup>&#x002B;</sup> subgroup than in M <sup>-</sup> subgroup ( &#967;&#178; = 7.49; P = 0.006, OR = 3.86; 95&#x0025; CI, 1.43-10.33). The difference between M <sup>-</sup> and controls did not observe statistically significant ( &#967;&#178; = 0.009; P = 0.92). <sec id="st1"><title>Conclusions:</title><p> Our results suggest that the presence of 5A polymorphism at the MMP-3 promoter region may favor the growth and the metastasis process in colorectal cancer patients and could be looked at as a risk factor for a worse prognosis.</p>
</sec>
<sec id="st2"><title>Materials and Methods:</title><p> In this case-control study 120 colorectal cancer patients and 100 controls were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) on the genomic deoxyribonucleic acid (DNA). The patients group was divided into different subgroups: a subgroup without metastatic activity (M <sup>-</sup> ) and a subgroup that had developed metastasis (M <sup>&#x002B;</sup> ). <sec id="st2"><title>Results:</title><p> There was a significant difference in frequency of the MMP-3 genotype between cases and controls (&#967;&#898; = 16.17; P = 0.0003). The 5A homozygote in patients and controls was significantly different. The frequency of the 5A allele among affected patients (67.91&#x0025;) was significantly higher than among the healthy controls (49&#x0025;; &#967;&#178; = 16.17, P = 0.00005). At the time of diagnosis, individual who was carrying the 5A allele was more represented in the M <sup>&#x002B;</sup> subgroup than in M <sup>-</sup> subgroup ( &#967;&#178; = 7.49; P = 0.006, OR = 3.86; 95&#x0025; CI, 1.43-10.33). The difference between M <sup>-</sup> and controls did not observe statistically significant ( &#967;&#178; = 0.009; P = 0.92). <sec id="st2"><title>Conclusions:</title><p> Our results suggest that the presence of 5A polymorphism at the MMP-3 promoter region may favor the growth and the metastasis process in colorectal cancer patients and could be looked at as a risk factor for a worse prognosis.</p>
</sec>
<sec id="st3"><title>Results:</title><p> There was a significant difference in frequency of the MMP-3 genotype between cases and controls (&#967;&#898; = 16.17; P = 0.0003). The 5A homozygote in patients and controls was significantly different. The frequency of the 5A allele among affected patients (67.91&#x0025;) was significantly higher than among the healthy controls (49&#x0025;; &#967;&#178; = 16.17, P = 0.00005). At the time of diagnosis, individual who was carrying the 5A allele was more represented in the M <sup>&#x002B;</sup> subgroup than in M <sup>-</sup> subgroup ( &#967;&#178; = 7.49; P = 0.006, OR = 3.86; 95&#x0025; CI, 1.43-10.33). The difference between M <sup>-</sup> and controls did not observe statistically significant ( &#967;&#178; = 0.009; P = 0.92). <sec id="st3"><title>Conclusions:</title><p> Our results suggest that the presence of 5A polymorphism at the MMP-3 promoter region may favor the growth and the metastasis process in colorectal cancer patients and could be looked at as a risk factor for a worse prognosis.</p>
</sec>
<sec id="st4"><title>Conclusions:</title><p> Our results suggest that the presence of 5A polymorphism at the MMP-3 promoter region may favor the growth and the metastasis process in colorectal cancer patients and could be looked at as a risk factor for a worse prognosis.</p>
</sec>
</abstract>
      <kwd-group><kwd>Invasion</kwd>
<kwd>MMP-3</kwd>
<kwd>polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)</kwd>
<kwd>single nucleotide polymorphism (SNP)</kwd>
</kwd-group>	
      
    </article-meta>
  </front>
  <body>
	<sec><title/>
</sec><sec><title>Introduction</title><p> </p>

<p>Variant genes are involving in extra cellular matrix (ECM) turnover, including matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). They have been considered as strong candidates for a genetic susceptibility factor to different diseases and cancer. Degradation of ECM is essential in many physiological processes, for example, during development, growth, and repair of tissue. <sup><xref ref-type="bibr" rid="ref1">1</xref></sup>,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup>,<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> Tumor cell invasion, metastasis and angiogenesis require controlled degradation of ECM. Increased expression of MMP enzymes is associated with invasion and metastasis of different malignances. <sup><xref ref-type="bibr" rid="ref4">4</xref></sup> MMPs comprise a family of enzymes that are able to degrade components of ECM. <sup><xref ref-type="bibr" rid="ref5">5</xref></sup> At least 26 human MMPs have been identified, which are classified according to their substrate specificity and structural similarities. <sup><xref ref-type="bibr" rid="ref2">2</xref></sup> These subgroups follow: Collagenases, gelatinases, stromelysins, matrilysins, and transmembrane MMPs. <sup><xref ref-type="bibr" rid="ref4">4</xref></sup>,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup></p>

<p> Colorectal cancer (CRC) is the most common malignancy of the gastrointestinal tract. It still carries a relatively poor prognosis despite recent improvement in early diagnosis, surgical techniques, and chemotherapy. About 40&#x0025; of patients who undergo operative resection will die within 5 years due to recurrent disease or metastasis. <sup><xref ref-type="bibr" rid="ref6">6</xref></sup>,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup>,<sup><xref ref-type="bibr" rid="ref8">8</xref></sup></p>

<p> Expression of the most MMPs is normally low in tissues and they are induced when remodeling of ECM is required. <sup><xref ref-type="bibr" rid="ref9">9</xref></sup> MMPs expression in tumor cells is regulated primarily at the transcriptional level, but there is also evidence of modulation of mRNA stability in response to growth factors and cytokines. <sup><xref ref-type="bibr" rid="ref9">9</xref></sup>,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup>,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> There is much evidence that MMPs play essential roles in migration, tumor growth, and development. <sup><xref ref-type="bibr" rid="ref5">5</xref></sup>,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup>,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup></p>

<p> The gene coding for MMP-3 is located on the long arm of chromosome-11 <sup><xref ref-type="bibr" rid="ref14">14</xref></sup> and consists of 10 exons, although there may be other shorter splice forms in addition to its full length transcript. <sup><xref ref-type="bibr" rid="ref15">15</xref></sup> MMP-3, also known as stromelysin-1, is up-regulated in a variety of tumors and it has been shown to influence tumor initiation and neoplastic risk. <sup><xref ref-type="bibr" rid="ref11">11</xref></sup>,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> MMP-3 is involved in the turnover of the ECM component. This enzyme degrades proteoglycans, collagen III, IV, V, and IX, laminin, fibronectin, gelatin, and elastin. Stromelysin-1 activates other members of the MMP family, such as MMP-1 and MMP-9. <sup><xref ref-type="bibr" rid="ref15">15</xref></sup>,<sup><xref ref-type="bibr" rid="ref16">16</xref></sup>,<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> A large number of polymorphisms have been reported in this gene, but the 5A/6A polymorphism in the promoter region has been most extensively investigated as this polymorphism increases the activity of the MMP-3 promoter. <sup><xref ref-type="bibr" rid="ref16">16</xref></sup>,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup>,<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> The adenine insertion/deletion polymorphism (5A/6A) at position -1171 of the MMP-3 gene promoter influences transcription factor binding and MMP-3 promoter activity. <sup><xref ref-type="bibr" rid="ref11">11</xref></sup>,<sup><xref ref-type="bibr" rid="ref16">16</xref></sup>,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> . In vitro assays of promoter activity showed that the 5A allele had 2- to 4-fold higher promoter activity than the 6A allele. <sup><xref ref-type="bibr" rid="ref10">10</xref></sup>,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> It has been reported that there is strong coloration between the MMP-3 polymorphism with breast, lung, and ovarian cancers. <sup><xref ref-type="bibr" rid="ref21">21</xref></sup>,<sup><xref ref-type="bibr" rid="ref22">22</xref></sup>,<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> There are some reports about correlation between 5A/5A polymorphism allele with progression and invasion activity of tumor cells, for example, in the breast cancer. <sup><xref ref-type="bibr" rid="ref10">10</xref></sup>,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup>,<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></p>

<p> The aim of this study was to determine whether 5A/6A polymorphism may be associated with initiation and development or/and progression and invasion of tumor cells of CRC in Iranian population.</p>


</sec><sec sec-type='materials|methods'><title>Materials and Methods</title><p> </p>

<p>Subjects</p>

<p> This case-control study includes 120 cancer patients and 100 healthy controls. Median age of cases was 53 years (age range, 32-74 years) and controls were age-matched (&#897; 3 years). This research is a retrospective case-control study. Cases were collected from a consecutive incident series with pathologically confirmation using colonoscopy and surgery; including 100 gender, age, and smoking status-matched healthy subjects without any diagnosis or history of cancer and any acute disease, were collected from Omid and Imam Khomeini hospitals, based in Isfahan and Tehran, respectively between 2009 and 2011. All the samples were collected from the patients with their permission. Detailed questionnaires, including clinical and family history, were initially collected. Patients were placed in two categories: with detectable metastasis position category (M <sup>&#x002B;</sup> ) and without detectable metastasis position category (M <sup>-</sup> ). CRC patients consisted of 60 nonmetastasis patients (Stages 1, 2, and 3) and 60 metastasis patients (Stage 4). Healthy control subjects were basically collected from central laboratories in the hospitals (tumor-free volunteer). In the cases of smoking habit, complete information about the former and present smoking habits, the numbers of cigarettes/day and the time of starting and quitting were inquired from each subject. The definition of smoker was considered as described by other related publications. Nonsmokers are classified as people smoking less than 5 cigarettes/day; individuals who formerly or currently smoked 5 or more cigarettes/day for at least 2 years were defined as smokers. <sup><xref ref-type="bibr" rid="ref11">11</xref></sup></p>

<p> DNA extraction</p>

<p> Five milliliters of venous blood from each subject was drawn into vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA) and stored at 4&#896;C for short study and -80&#896;C for long study. Genomic deoxyribonucleic acid (DNA) was extracted using salting out method as published by Miller et al., with some modifications. <sup><xref ref-type="bibr" rid="ref24">24</xref></sup></p>

<p> MMP-3 SNP genotyping</p>

<p> The MMP-3 genotype was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. The PCR primers were designed in previous study and checked by OLIGO 7 primer analysis software. A mutation from A to G at the second nucleotide close to the 3&#8242;end of the forward primer was made to create a PsyI recognition site in the case of the 5A allele (shown "g" in the forward primer sequences). Primers sequences are shown in <xref ref-type="table" rid="T1">Table 1</xref>. PCR reaction was performed in a 25 &#901;l volume containing 100 ng of DNA template (genomic DNA), 2.5 &#901;l of 10&#935; PCR buffer, 200 mM MgCl <sub>2</sub> , 1 unit of taq DNA polymerase (Cinnagen, Iran), 0.2 mM dNTPs, and 200 pM forward and reverse primers. The PCR cycling conditions were 3 min at 94&#896;C followed by 30 cycles including: 30 s at 94&#896;C, 30 s at 65&#896;C, 30 s at 72&#896;C, and final step at 72&#896;C for 10 min to complete extension of all PCR fragments. A 5 &#901;l PCR product was digested overnight at 37&#896;C in a 15 &#901;l reaction containing 5 units of PsyI enzyme (fermentase- Germany). After digestion, the digested fragments were subjected to electrophoresis on a 3&#x0025; agarose gel stained with ethidium bromide. As expected, the 5A alleles would be represented by DNA bands of 97 and 32 bp (the small one could not be detected on the agarose gel electrophoresis) and the 6A alleles by a DNA band of 129 bp. For a negative control distilled water was used instead of DNA in the reaction system for each PCR.{Table 1}</p>

<p> Statistical analysis</p>

<p> Statistical analyses were performed using the SPSS 12 Software package. Hardy-Weinberg analyses were performed to compare the observed and expected genotype frequency using the &#967;&#898; test. The odd ratio (OR) and 95&#x0025; confidence interval (95&#x0025; CI) were calculated using an unconditional logistic regression model and adjusted for age and sex. They were also calculated as an index of the association of genotype and risk of CRC initiation and metastatic activity. All statistical tests were two-sided, and a P value of less than 0.05 was considered significant.</p>


</sec><sec><title>Results</title><p> </p>

<p>At the time of CRC diagnosis, patients were aged between 32 and 74 years, with a mean of 53 years, and controls were age-matched (&#897; 3 years). The MMP-3 genotype was successfully determined in 120 patients and 100 healthy controls <xref ref-type="fig" rid="F1">Figure 1</xref>. There were no significant difference in the frequency of the MMP-3 genotype according to gender and age.<fig id="F1"><label>Figure 1</label><caption><p><italic>Stromelysin-1</italic> genotyping using PCR-RFLP method. 1 and 5, 5A/5A genotype. 2, 3, 6, and 7, 6A/5A genotype. 4, 6A/6A genotype. L, 50 bp DNA Ladder</p>
</caption><alt-text>Figure 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JResMedSci_2012_17_10_962_113208_u5.tif"/></fig></p>

<p>Of the 120 patients participate in this study, 11 subjects (9.17&#x0025;) were homozygous for the 6A allele, 54 subjects (45&#x0025;) were homozygous for the 5A allele, and 55 subjects (45.83&#x0025;) were heterozygous. The frequency of allele 5A was 49&#x0025; in controls and 67.91&#x0025; in cases, but the frequency of allele 6A was 51&#x0025; in controls and 32.09&#x0025; in cases <xref ref-type="table" rid="T2">Table 2</xref>. As shown in the <xref ref-type="table" rid="T2">Table 2</xref>, the MMP-3 genotype and allelic distribution between CRC patients and healthy control were significantly different (&#967;&#178; = 16.17, P = 0.0003; &#967;&#178; = 16.17, P = 0.00005, respectively).{Table 2}</p>

<p>The 5A homozygote genotype was more frequent among patients than the healthy control groups [OR = 5.31, 95&#x0025; CI, 2.28-12.38; P = 0.000; <xref ref-type="table" rid="T3">Table 3</xref>]. Therefore, 5A/5A genotype was used as reference and at this case 5A/6A genotype (individual who was carrying the 5A allele) showed significantly influence on the risk of CRC (OR = 2.04, 95&#x0025; CI, 1.10-3.76).{Table 3}</p>

<p>By dividing patients into metastatic activity subgroup and nonmetastatic activity subgroup, as shown in <xref ref-type="table" rid="T4">Table 4</xref>, individual who was carrying the 5A allele was more frequent in metastasis subgroup than the healthy controls (OR = 3.86, 95&#x0025; CI, 1.43-10.33; P = 0.006). However, no statistical differences were observed in nonmetastasis subgroup versus healthy controls (&#967;&#178; = 0.009, P = 0.92). Therefore, it was found that individual carrying the 5A allele with OR of 3.86 (95&#x0025; CI, 1.43-10.33) compared with those who were 6A/6A genotype expose on median increased risk for metastatic activity of CRC.{Table 4}</p>

<p>According to our results (data not shown), it is demonstrated that 5A/5A genotype and even genotypes with at least one 5A allele, could have important effect on the age of onset of CRC initiation (62.33 vs 64.0, P = 0.0001). However, 5A homozygote individuals are spatially at risk for early onset of metastasis spread of CRC (69.42 vs 67.21, P = 0.0011).</p>


</sec><sec><title>Discussion</title><p> </p>

<p>Many studies show association of MMP polymorphism with initiation of cancer and especially with invasion risk and metastatic activity of different types of cancers such as breast, lung, and colorectal. <sup><xref ref-type="bibr" rid="ref10">10</xref></sup>,<sup><xref ref-type="bibr" rid="ref11">11</xref></sup>,<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> Our previous studies showed the relationship of MMP-1 polymorphism with invasion risk of CRC <sup><xref ref-type="bibr" rid="ref8">8</xref></sup> and breast cancer in Iranian population. <sup><xref ref-type="bibr" rid="ref13">13</xref></sup> We also demonstrated a strong association of MMP-3 polymorphism with tumor cell progression and metastasis of breast cancer in Iranian population. <sup><xref ref-type="bibr" rid="ref12">12</xref></sup> The most of cancer deaths are resulting from tumor spread and metastasis, the process that is accompanied by degradation of components of the basal membrane and the ECM. <sup><xref ref-type="bibr" rid="ref5">5</xref></sup> It has been demonstrated that those individuals carrying the 5A allele (5A/5A and 5A/6A genotypes) of MMP-3 associate with tumor cell progression and metastatic activity. <sup><xref ref-type="bibr" rid="ref25">25</xref></sup> It has been suggested that the higher transcriptional activity of 5A allele may enhances tumor invasiveness. <sup><xref ref-type="bibr" rid="ref10">10</xref></sup>,<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Our present statistical analyses did not show strong association between the 5A allele and M <sup>-</sup> CRC group by comparison M <sup>-</sup> versus healthy control group at the time of diagnosis (OR = 0.96, 95&#x0025; CI, 0.47-1.98). Our present results suggest that MMP-3 plays significant roles in spread and cell progression of CRC metastatic activity. Therefore, over expression of MMP-3 due to 5A promoter polymorphism may be a facilitating factor for CRC invasion and metastasis rather than initiation of CRC. The 5A allelic and 5A/5A genotypic frequencies in patient were 67.91&#x0025; and 45&#x0025;, respectively. The results showed that 5A/5A genotype and those individuals carrying the 5A allele were frequent in M <sup>&#x002B;</sup> group and therefore, could be correlated to CRC invasion and metastasis (&#967;&#178; = 7.49, P = 0.006).</p>

<p>Present study demonstrated a weak association between MMP-3 promoter polymorphism and the initiation of CRC. But it demonstrated an important statistical association between those individual carrying the 5A allele and tumor cell progression and metastasis of CRC. Our results show that 5A allele may be a moderate risk factor for invasion/ progression and metastatic activity of CRC. Therefore, MMP-3 genotype determination could be a moderate genetic marker to identify prone for development of tumor cell progression and invasion of CRC. However, it is conceivable that detection of cases with high potential for development of invasion and metastatic activity and then prevention of their development are important to enhance the survival rate of CRC patients and to treat the cancer.</p>
</sec>
  </body>
  <back>
	
	
	    <ref-list><ref id="ref1">
<label>1</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Johansson</surname>
  <given-names>N</given-names>
</name>
<name> 
  <surname>Ahonen</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>K&#228;h&#228;ri</surname>
  <given-names>VM</given-names>
</name>
</person-group><article-title>Matrix metalloproteinases in tumor invasion</article-title><source>Cell Mol Life Sci</source>
<year>2000</year>
<volume>57</volume>
<fpage>5</fpage>
<lpage>15</lpage>
</nlm-citation>
</ref>
<ref id="ref2">
<label>2</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>John</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Tuszynsky</surname>
  <given-names>G</given-names>
</name>
</person-group><article-title>The role of matrix metalloproteinase in tumor angiogenesis and tumor metastasis</article-title><source>Pathol Oncol Res</source>
<year>2001</year>
<volume>7</volume>
<fpage>14</fpage>
<lpage>23</lpage>
</nlm-citation>
</ref>
<ref id="ref3">
<label>3</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Sternlicht</surname>
  <given-names>MD</given-names>
</name>
<name> 
  <surname>Werb</surname>
  <given-names>Z</given-names>
</name>
</person-group><article-title>How matrix metalloproteinases regulate cell behavior</article-title><source>Annu Rev Cell Dev Biol</source>
<year>2001</year>
<volume>17</volume>
<fpage>463</fpage>
<lpage>516</lpage>
</nlm-citation>
</ref>
<ref id="ref4">
<label>4</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Chambers</surname>
  <given-names>AF</given-names>
</name>
<name> 
  <surname>Matrisian</surname>
  <given-names>LA</given-names>
</name>
</person-group><article-title>Changing views on the role of matrix metalloproteinases in metastasis</article-title><source>J Natl Cancer Inst</source>
<year>1997</year>
<volume>89</volume>
<fpage>1260</fpage>
<lpage>70</lpage>
</nlm-citation>
</ref>
<ref id="ref5">
<label>5</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Folgueras</surname>
  <given-names>AR</given-names>
</name>
<name> 
  <surname>Pendas</surname>
  <given-names>AM</given-names>
</name>
<name> 
  <surname>Sanchez</surname>
  <given-names>LM</given-names>
</name>
<name> 
  <surname>Lopez-Otin</surname>
  <given-names>C</given-names>
</name>
</person-group><article-title>Matrix metalloproteinases in cancer: From new functions to improved inhibition strategies</article-title><source>Int J Dev Biol</source>
<year>2004</year>
<volume>48</volume>
<fpage>411</fpage>
<lpage>24</lpage>
</nlm-citation>
</ref>
<ref id="ref6">
<label>6</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Zinzindohoue</surname>
  <given-names>F</given-names>
</name>
<name> 
  <surname>Lecomte</surname>
  <given-names>T</given-names>
</name>
<name> 
  <surname>Ferraz</surname>
  <given-names>JM</given-names>
</name>
<name> 
  <surname>Houllier</surname>
  <given-names>AM</given-names>
</name>
<name> 
  <surname>Cugence</surname>
  <given-names>PH</given-names>
</name>
<name> 
  <surname>Berger</surname>
  <given-names>A</given-names>
</name>
 <etal/>
</person-group><article-title>Prognostic significant of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer</article-title><source>Clin Cancer Res</source>
<year>2005</year>
<volume>11</volume>
<fpage>594</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="ref7">
<label>7</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Zucker</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Vacirca</surname>
  <given-names>J</given-names>
</name>
</person-group><article-title>Role of matrix metalloproteinase (MMPs) in colorectal cancer</article-title><source>Cancer Metastasis Rev</source>
<year>2004</year>
<volume>23</volume>
<fpage>101</fpage>
<lpage>17</lpage>
</nlm-citation>
</ref>
<ref id="ref8">
<label>8</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Kouhkan</surname>
  <given-names>F</given-names>
</name>
<name> 
  <surname>Motovali-Bashi</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Hojati</surname>
  <given-names>Z</given-names>
</name>
</person-group><article-title>The influence of interstitial collagenase-1 genotype polymorphism on colorectal cancer risk in Iranian population</article-title><source>Cancer Invest</source>
<year>2008</year>
<volume>26</volume>
<fpage>836</fpage>
<lpage>42</lpage>
</nlm-citation>
</ref>
<ref id="ref9">
<label>9</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Sternlicht</surname>
  <given-names>MD</given-names>
</name>
<name> 
  <surname>Bissell</surname>
  <given-names>MJ</given-names>
</name>
<name> 
  <surname>Werb</surname>
  <given-names>Z</given-names>
</name>
</person-group><article-title>The matrix metalloproteinase stromelysin-1 acts as natural mammary tumor promoter</article-title><source>Oncogene</source>
<year>2000</year>
<volume>19</volume>
<fpage>1102</fpage>
<lpage>13</lpage>
</nlm-citation>
</ref>
<ref id="ref10">
<label>10</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Krippl</surname>
  <given-names>P</given-names>
</name>
<name> 
  <surname>Langsenlehner</surname>
  <given-names>U</given-names>
</name>
<name> 
  <surname>Renner</surname>
  <given-names>W</given-names>
</name>
<name> 
  <surname>Yazdani-Biuki</surname>
  <given-names>B</given-names>
</name>
<name> 
  <surname>Koppel</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Leithner</surname>
  <given-names>A</given-names>
</name>
 <etal/>
</person-group><article-title>The 5A/6A polymorphism of matrix metalloproteinase-3 gene promoter and breast cancer</article-title><source>Clin Cancer Res</source>
<year>2004</year>
<volume>10</volume>
<fpage>3518</fpage>
<lpage>20</lpage>
</nlm-citation>
</ref>
<ref id="ref11">
<label>11</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Fang</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Jin</surname>
  <given-names>X</given-names>
</name>
<name> 
  <surname>Wang</surname>
  <given-names>R</given-names>
</name>
<name> 
  <surname>Li</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Guo</surname>
  <given-names>W</given-names>
</name>
<name> 
  <surname>Wang</surname>
  <given-names>N</given-names>
</name>
 <etal/>
</person-group><article-title>Polymorphism in the MMP-1 and MMP-3 promoter and non-small cell lung carcinoma in the north China</article-title><source>Carcinogenesis</source>
<year>2005</year>
<volume>26</volume>
<fpage>481</fpage>
<lpage>6</lpage>
</nlm-citation>
</ref>
<ref id="ref12">
<label>12</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Motovali-Bashi</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Hojati</surname>
  <given-names>Z</given-names>
</name>
<name> 
  <surname>Hajihoseini</surname>
  <given-names>S</given-names>
</name>
</person-group><article-title>The role of matrix metalloproteinase 3 functional 5A/6A promoter polymorphism in tumor progression and metastasis of breast cancer</article-title><source>Iranian Journal of Biotechnology</source>
<year>2008</year>
<volume>6</volume>
<fpage>45</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="ref13">
<label>13</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Motovali-Bashi</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Hojati</surname>
  <given-names>Z</given-names>
</name>
<name> 
  <surname>Kouhkan</surname>
  <given-names>F</given-names>
</name>
</person-group><article-title>Genetic variation in MMP1 promoter region and breast cancer susceptibility</article-title><source>Journal of Sciences, Islamic Republic of Iran</source>
<year>2008</year>
<volume>19</volume>
<fpage>9</fpage>
<lpage>14</lpage>
</nlm-citation>
</ref>
<ref id="ref14">
<label>14</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Formstone</surname>
  <given-names>CJ</given-names>
</name>
<name> 
  <surname>Byrd</surname>
  <given-names>PJ</given-names>
</name>
<name> 
  <surname>Ambrose</surname>
  <given-names>HJ</given-names>
</name>
<name> 
  <surname>Riley</surname>
  <given-names>JH</given-names>
</name>
<name> 
  <surname>Hernandez</surname>
  <given-names>D</given-names>
</name>
<name> 
  <surname>McConville</surname>
  <given-names>CM</given-names>
</name>
 <etal/>
</person-group><article-title>The order and orientation of a cluster of metalloproteinase genes, stromelysin 2, collagenase, and stromelysin, together with D11S385, on chromosome 11q22-q23</article-title><source>Genomics</source>
<year>1993</year>
<volume>16</volume>
<fpage>289</fpage>
<lpage>91</lpage>
</nlm-citation>
</ref>
<ref id="ref15">
<label>15</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Ye</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Eriksson</surname>
  <given-names>P</given-names>
</name>
<name> 
  <surname>Hamsten</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Kurkinen</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Humphries</surname>
  <given-names>SE</given-names>
</name>
<name> 
  <surname>Henney</surname>
  <given-names>AM</given-names>
</name>
</person-group><article-title>Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression</article-title><source>J Biol Chem</source>
<year>1996</year>
<volume>271</volume>
<fpage>13055</fpage>
<lpage>60</lpage>
</nlm-citation>
</ref>
<ref id="ref16">
<label>16</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Zhang</surname>
  <given-names>J</given-names>
</name>
<name> 
  <surname>Jin</surname>
  <given-names>X</given-names>
</name>
<name> 
  <surname>Fang</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Li</surname>
  <given-names>Y</given-names>
</name>
<name> 
  <surname>Wang</surname>
  <given-names>R</given-names>
</name>
<name> 
  <surname>Guo</surname>
  <given-names>W</given-names>
</name>
 <etal/>
</person-group><article-title>The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric adeno carcinoma</article-title><source>Carcinogenesis</source>
<year>2004</year>
<volume>25</volume>
<fpage>2519</fpage>
<lpage>24</lpage>
</nlm-citation>
</ref>
<ref id="ref17">
<label>17</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Gnasso</surname>
  <given-names>A</given-names>
</name>
<name> 
  <surname>Motti</surname>
  <given-names>G</given-names>
</name>
<name> 
  <surname>Irace</surname>
  <given-names>C</given-names>
</name>
<name> 
  <surname>Carallo</surname>
  <given-names>C</given-names>
</name>
<name> 
  <surname>Liberatoscioli</surname>
  <given-names>L</given-names>
</name>
<name> 
  <surname>Bernadini</surname>
  <given-names>S</given-names>
</name>
 <etal/>
</person-group><article-title>Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects</article-title><source>Arterioscler Thromb Vasc Biol</source>
<year>2000</year>
<volume>20</volume>
<fpage>1600</fpage>
<lpage>8</lpage>
</nlm-citation>
</ref>
<ref id="ref18">
<label>18</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Holliday</surname>
  <given-names>DL</given-names>
</name>
<name> 
  <surname>Hughes</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Shaw</surname>
  <given-names>JA</given-names>
</name>
<name> 
  <surname>Walker</surname>
  <given-names>RA</given-names>
</name>
<name> 
  <surname>Jones</surname>
  <given-names>JL</given-names>
</name>
</person-group><article-title>Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: Matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion</article-title><source>Breast Cancer Res</source>
<year>2007</year>
<volume>9</volume>
<fpage>R67</fpage>
</nlm-citation>
</ref>
<ref id="ref19">
<label>19</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Biondi</surname>
  <given-names>ML</given-names>
</name>
<name> 
  <surname>Turri</surname>
  <given-names>O</given-names>
</name>
<name> 
  <surname>Leviti</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Seminati</surname>
  <given-names>R</given-names>
</name>
<name> 
  <surname>Cecchini</surname>
  <given-names>F</given-names>
</name>
<name> 
  <surname>Bernini</surname>
  <given-names>M</given-names>
</name>
 <etal/>
</person-group><article-title>MMP1 and MMP3 polymorphism in promoter regions and cancer</article-title><source>Clin Chem</source>
<year>2000</year>
<volume>46</volume>
<fpage>2023</fpage>
<lpage>4</lpage>
</nlm-citation>
</ref>
<ref id="ref20">
<label>20</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Deguara</surname>
  <given-names>J</given-names>
</name>
<name> 
  <surname>Burnand</surname>
  <given-names>KG</given-names>
</name>
<name> 
  <surname>Berg</surname>
  <given-names>J</given-names>
</name>
<name> 
  <surname>Green</surname>
  <given-names>P</given-names>
</name>
<name> 
  <surname>Lewis</surname>
  <given-names>CM</given-names>
</name>
<name> 
  <surname>Chinien</surname>
  <given-names>G</given-names>
</name>
 <etal/>
</person-group><article-title>An increased frequency of the 5A allele in the promoter region of the MMP3 gene is associated with abdominal aortic aneurysms</article-title><source>Hum Mol Genet</source>
<year>2007</year>
<volume>16</volume>
<fpage>3002</fpage>
<lpage>7</lpage>
</nlm-citation>
</ref>
<ref id="ref21">
<label>21</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Boonrao</surname>
  <given-names>M</given-names>
</name>
<name> 
  <surname>Yodkeeree</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Ampasavate</surname>
  <given-names>C</given-names>
</name>
<name> 
  <surname>Anuchapreeda</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Limtrakul</surname>
  <given-names>P</given-names>
</name>
</person-group><article-title>The inhibitory effect of turmeric curcuminoids on matrix metalloproteinase-3 secretion in human invasive breast carcinoma cells</article-title><source>Arch Pharm Res</source>
<year>2010</year>
<volume>33</volume>
<fpage>989</fpage>
<lpage>98</lpage>
</nlm-citation>
</ref>
<ref id="ref22">
<label>22</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Lim</surname>
  <given-names>BJ</given-names>
</name>
<name> 
  <surname>Jung</surname>
  <given-names>SS</given-names>
</name>
<name> 
  <surname>Choi</surname>
  <given-names>SY</given-names>
</name>
<name> 
  <surname>Lee</surname>
  <given-names>CS</given-names>
</name>
</person-group><article-title>Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance</article-title><source>Mol Med Report</source>
<year>2010</year>
<volume>3</volume>
<fpage>43</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="ref23">
<label>23</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Johnson</surname>
  <given-names>EL</given-names>
</name>
<name> 
  <surname>Singh</surname>
  <given-names>R</given-names>
</name>
<name> 
  <surname>Singh</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Johnson-Holiday</surname>
  <given-names>CM</given-names>
</name>
<name> 
  <surname>Grizzle</surname>
  <given-names>WE</given-names>
</name>
<name> 
  <surname>Partridge</surname>
  <given-names>EE</given-names>
</name>
 <etal/>
</person-group><article-title>CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression and invasion</article-title><source>World J Surg Oncol</source>
<year>2010</year>
<volume>8</volume>
<fpage>62</fpage>
</nlm-citation>
</ref>
<ref id="ref24">
<label>24</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Miller</surname>
  <given-names>SA</given-names>
</name>
<name> 
  <surname>Dykes</surname>
  <given-names>DD</given-names>
</name>
<name> 
  <surname>Polesky</surname>
  <given-names>HF</given-names>
</name>
</person-group><article-title>A simple salting out proceduce for extracting DNA from human nucleated cells</article-title><source>Nucleic Acids Res</source>
<year>1988</year>
<volume>16</volume>
<fpage>1215</fpage>
</nlm-citation>
</ref>
<ref id="ref25">
<label>25</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Rdisky</surname>
  <given-names>DC</given-names>
</name>
<name> 
  <surname>Levy</surname>
  <given-names>DD</given-names>
</name>
<name> 
  <surname>Littlepage</surname>
  <given-names>LE</given-names>
</name>
<name> 
  <surname>Liu</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Nelson</surname>
  <given-names>CM</given-names>
</name>
<name> 
  <surname>Fata</surname>
  <given-names>JE</given-names>
</name>
 <etal/>
</person-group><article-title>Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability</article-title><source>Nature</source>
<year>2005</year>
<volume>436</volume>
<fpage>123</fpage>
<lpage>7</lpage>
</nlm-citation>
</ref>
<ref id="ref26">
<label>26</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"><name> 
  <surname>Blons</surname>
  <given-names>H</given-names>
</name>
<name> 
  <surname>Gad</surname>
  <given-names>S</given-names>
</name>
<name> 
  <surname>Zinzindohoue</surname>
  <given-names>F</given-names>
</name>
<name> 
  <surname>Maniere</surname>
  <given-names>I</given-names>
</name>
<name> 
  <surname>Beauregard</surname>
  <given-names>J</given-names>
</name>
<name> 
  <surname>Tregouet</surname>
  <given-names>D</given-names>
</name>
 <etal/>
</person-group><article-title>Matrix metalloproteinase 3 polymorphism: A predictive factor of response to neoadjuvent chemotherapy in head and neck squamous cell carcinoma</article-title><source>Clin Cancer Res</source>
<year>2004</year>
<volume>10</volume>
<fpage>2594</fpage>
<lpage>9</lpage>
</nlm-citation>
</ref>
<ref id="ref27">
<label>27</label>
<nlm-citation citation-type="journal">
<person-group person-group-type="author"></person-group><article-title></article-title><source></source>
<year></year>
<volume></volume>
<fpage></fpage>
</nlm-citation>
</ref>
</ref-list>

  </back>
	
</article> 




